1.051ºÚÁϳԹÏÍøLizzet Verdi/author/lverdi/Onco360® Has Been Selected as a National Specialty Pharmacy Partner for Itovebi™ (inavolisib) - 51ºÚÁϳԹÏÍørich600338<blockquote class="wp-embedded-content" data-secret="gWiC80DogZ"><a href="/media-hub/4975/">Onco360® Has Been Selected as a National Specialty Pharmacy Partner for Itovebi™ (inavolisib)</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="/media-hub/4975/embed/#?secret=gWiC80DogZ" width="600" height="338" title="“Onco360® Has Been Selected as a National Specialty Pharmacy Partner for Itovebi™ (inavolisib)” — 51ºÚÁϳԹÏÍø" data-secret="gWiC80DogZ" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script type="text/javascript">
/* <![CDATA[ */
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
/* ]]> */
</script>
/wp-content/uploads/2024/11/2024-Onco-Itovebi.jpg600400Onco360® has been selected as a pharmacy partner by Genentech, a member of the Roche Group, for ITOVEBI™ (inavolisib) which is indicated, in combination with palbociclib and fulvestrant, for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy..